KOLMAR BNH Co.,Ltd. (KOSDAQ:200130)

South Korea flag South Korea · Delayed Price · Currency is KRW
15,750
-700 (-4.26%)
Sep 19, 2025, 3:30 PM KST
-4.26%
Market Cap445.65B
Revenue (ttm)590.33B
Net Income (ttm)14.05B
Shares Out28.29M
EPS (ttm)488.70
PE Ratio32.23
Forward PEn/a
Dividend308.00 (1.96%)
Ex-Dividend DateAug 28, 2025
Volume196,605
Average Volume259,237
Open16,240
Previous Close16,450
Day's Range15,620 - 16,370
52-Week Range11,030 - 20,300
Beta0.48
RSI49.84
Earnings DateNov 14, 2025

About KOLMAR BNH

Kolmar BNH Co., Ltd. engages in the research and development of materials used in the functional health food and cosmetics market in South Korea and internationally. The company offers cosmetics; and provides total functional health food original development manufacturing services, such as manufacturing tablets, hard capsules, soft capsules, liquids, gels, powder dosage, and various new formulation forms. It offers packaging products, such as PTP/multi-PTP, powder stick/pouch, three-side cloth, four-side, and liquid stick packaging; and ODM con... [Read more]

Founded 2004
Employees 476
Stock Exchange KOSDAQ
Ticker Symbol 200130
Full Company Profile

Financial Performance

In 2024, KOLMAR BNH's revenue was 615.64 billion, an increase of 6.23% compared to the previous year's 579.55 billion. Earnings were 18.05 billion, a decrease of -8.41%.

Financial Statements

News

Kolmar BNH Revolutionizes ESG with HemoHIM, an Eco-friendly Health Supplement

SEOUL, South Korea — Kolmar BNH (KRX: 200130), a leading Korean health functional food Original Development Manufacturing (ODM) firm, is at the forefront of Environmental, Social, and Governance (ESG)...

10 months ago - Financial Post

HemoHim Manufacturer Kolmar BNH Receives NAI Classification from the US FDA

SEOUL, South Korea — ‘HemoHim,’ an immune-boosting health supplement from Kolmar BNH (KRX: 200130), has earned international recognition for its quality from both the U.S. Food and Drug Administration...

11 months ago - Financial Post